ACRS Aclaris Therapeutics Inc

Price (delayed)

$1.235

Market cap

$87.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$48.14M

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
The company's revenue rose by 46% QoQ and by 5% YoY
Aclaris Therapeutics's EPS has increased by 23% QoQ and by 4.5% YoY
Aclaris Therapeutics's quick ratio has shrunk by 61% YoY but it has increased by 2.1% QoQ
ACRS's gross profit has soared by 59% from the previous quarter but it is down by 26% YoY
ACRS's equity is down by 20% YoY

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
70.93M
Market cap
$87.59M
Enterprise value
$48.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
2.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
Earnings
Revenue
$31.25M
EBIT
-$88.85M
EBITDA
-$87.99M
Free cash flow
-$79.63M
Per share
EPS
-$1.27
Free cash flow per share
-$1.14
Book value per share
$2.22
Revenue per share
$0.45
TBVPS
$2.82
Balance sheet
Total assets
$197.41M
Total liabilities
$40.23M
Debt
$426,000
Equity
$157.18M
Working capital
$97.9M
Liquidity
Debt to equity
0
Current ratio
4.16
Quick ratio
3.86
Net debt/EBITDA
0.45
Margins
EBITDA margin
-281.6%
Gross margin
42.1%
Net margin
-283.1%
Operating margin
-397.6%
Efficiency
Return on assets
-40.2%
Return on equity
-52.8%
Return on invested capital
-58.5%
Return on capital employed
-53.4%
Return on sales
-284.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
3.78%
1 week
2.07%
1 month
1.23%
1 year
-90.09%
YTD
17.62%
QTD
17.62%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$31.25M
Gross profit
$13.17M
Operating income
-$124.26M
Net income
-$88.48M
Gross margin
42.1%
Net margin
-283.1%
ACRS's gross profit has soared by 59% from the previous quarter but it is down by 26% YoY
ACRS's net margin is up by 47% from the previous quarter and by 3.1% YoY
The company's revenue rose by 46% QoQ and by 5% YoY
The operating income has decreased by 46% YoY and by 7% from the previous quarter

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
0.56
P/S
2.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
Aclaris Therapeutics's EPS has increased by 23% QoQ and by 4.5% YoY
ACRS's P/B is 85% below its 5-year quarterly average of 3.6 and 80% below its last 4 quarters average of 2.7
ACRS's equity is down by 20% YoY
ACRS's P/S is 96% below its 5-year quarterly average of 61.6 and 84% below its last 4 quarters average of 16.5
The company's revenue rose by 46% QoQ and by 5% YoY

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has increased by 47% QoQ and by 2.7% YoY
The company's return on equity fell by 27% YoY but it rose by 18% QoQ
Aclaris Therapeutics's return on invested capital has decreased by 20% YoY but it has increased by 16% QoQ
The ROA has decreased by 19% YoY but it has increased by 18% from the previous quarter

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's quick ratio has shrunk by 61% YoY but it has increased by 2.1% QoQ
ACRS's current ratio has dropped by 61% year-on-year and by 8% since the previous quarter
ACRS's debt is 100% less than its equity
ACRS's debt is down by 38% YoY but it is up by 37% from the previous quarter
ACRS's equity is down by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.